SARTORIUS-AG
The Sartorius Group sold its Industrial Technologies Division with economic effect as of January 1, 2015. Therefore, Sartorius Group reporting for the full year of 2014 was already based on continuing operations according to the IFRS International Financial Reporting Standards (see the 2014 Annual Report). In addition to the disclosures made in the annual report, the following supplementary information is provided on business development at the Group and division levels for the regular reporting periods up to and including the full year of 2014 for better comparison with reported future quarterly results:
| Sartorius Group | ||||||||
| in millions of €, unless otherwise specified | ||||||||
| 3M 2014 | 6M 2014 | 9M 2014 | FY 2014 | |||||
| Order intake | 225.1 | 440.5 | 658.1 | 929.2 | ||||
| Sales revenue | 203.1 | 423.0 | 645.5 | 891.2 | ||||
| Cost of sales | -105.1 | -218.6 | -333.3 | -461.6 | ||||
| Gross profit on sales | 98.0 | 204.4 | 312.2 | 429.6 | ||||
| Selling and distribution costs | -48.7 | -98.3 | -147.2 | -200.2 | ||||
| Research and development expenses | -13.4 | -25.3 | -38.2 | -50.4 | ||||
| General administrative expenses | -14.1 | -27.9 | -41.9 | -58.3 | ||||
| Other operating income | expenses | 3.4 | 5.1 | 5.2 | 5.5 | ||||
| Earnings before interest and taxes (EBIT) | 25.2 | 58.0 | 90.2 | 126.2 | ||||
| Financial result | -4.4 | -10.0 | -16.3 | -29.9 | ||||
| Profit before tax | 20.8 | 48.0 | 73.9 | 96.3 | ||||
| Income taxes | -6.3 | -17.5 | -25.1 | -32.4 | ||||
| Profit after tax from continuing operations | 14.6 | 30.5 | 48.7 | 63.9 | ||||
| Profit after tax from discontinued operation | 0.5 | 1.6 | 3.4 | 4.5 | ||||
| Net profit for the period | 15.1 | 32.1 | 52.1 | 68.4 | ||||
| Attributable to: | ||||||||
| Equity holders of Sartorius AG | 11,0 | 23.1 | 37.8 | 48.5 | ||||
| Non-controlling interest | 4.0 | 9.0 | 14.3 | 19.9 | ||||
| Reconciliation to Underlying EBITDA | ||||||||
| Extraordinary items | 1.2 | 2.0 | 4.0 | 8.3 | ||||
| Amortization | depreciation | 12.2 | 24.8 | 37.8 | 52.3 | ||||
| Underlying EBITDA1) | 38.7 | 84.8 | 131.9 | 186.8 | ||||
| Underlying EBITA margin in %1) | 19.0 | 20.1 | 20.4 | 21.0 | ||||
| Sartorius Divisions | ||||||||
| € in millions, unless otherwise specified | ||||||||
| 3M 2014 | 6M 2014 | 9M 2014 | FY 2014 | |||||
| Bioprocess Solutions | ||||||||
| Order intake | 158.1 | 304.9 | 460.3 | 652.7 | ||||
| Sales revenue | 137.7 | 291.1 | 444.7 | 615.6 | ||||
| Underlying EBITDA1) | 29.6 | 66.4 | 103.0 | 145.6 | ||||
| Underlying EBITDA margin in %1) | 21.5 | 22.8 | 23.2 | 23.7 | ||||
| Lab Products & Services | ||||||||
| Order intake | 67.0 | 135.7 | 197.8 | 276.5 | ||||
| Sales revenue | 65.4 | 131.9 | 200.8 | 275.5 | ||||
| Underlying EBITDA1) | 9.1 | 18.4 | 29.0 | 41.2 | ||||
| Underlying EBITDA margin in %1) | 13.9 | 14.0 | 14.4 | 15.0 | ||||
| Reconciliation to the Relevant Net Profit | ||||||||
| in millions of €, unless otherwise specified | ||||||||
| 3M 2014 | 6M 2014 | 9M 2014 | FY 2014 | |||||
| Earnings before interest and taxes (EBIT) | 25.2 | 58.0 | 90.2 | 126.2 | ||||
| Extraordinary items | 1.2 | 2.0 | 4.0 | 8.3 | ||||
| Amortization | 3.5 | 7.0 | 10.6 | 14.0 | ||||
| Normalized financial result2) | -4.3 | -10.0 | -14.4 | -20.2 | ||||
| Normalized income tax3) | -7.7 | -17.1 | -27.1 | -38.5 | ||||
| Underlying earnings after taxes | 17.9 | 39.9 | 63.3 | 89.8 | ||||
| Non-controlling interest | -4.7 | -10.6 | -16.6 | -23.7 | ||||
| Underlying earnings after taxes and non-controlling interest | 13.3 | 29.3 | 46.6 | 66.1 | ||||
| per ordinary share (in €) | 0.77 | 1.71 | 2.72 | 3.87 | ||||
| per preference share (in €) | 0.79 | 1.73 | 2.74 | 3.89 | ||||
| Relevant net profit after non-controlling interest4) | 13.8 | 31.3 | 50.5 | 73.7 | ||||
| per ordinary share (in €) | 0.80 | 1.82 | 2.96 | 4.31 | ||||
| per preference share (in €) | 0.82 | 1.84 | 2.98 | 4.33 | ||||
|
1) Adjusted for extraordinary items |
||||||||
|
2) Financial result excluding fair value adjustments of hedging instruments and non-periodic expenses and income |
||||||||
|
3) Underlying income tax, based on the underlying profit before taxes and non-cash amortization |
||||||||
|
4) Including discontinued operation |
||||||||
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider covering the two segments of Bioprocess Solutions and Lab Products & Services. In 2014, the technology group earned sales revenue of 891.2 million euros. Founded in 1870, the Goettingen-based company currently employs more than 5,500 persons. The major areas of activity of its Bioprocess Solutions segment cover filtration, fluid management, fermentation, cell cultivation and purification, and focus on production processes in the biopharmaceutical industry. The Lab Products & Services segment primarily manufactures laboratory instruments and lab consumables. Sartorius has its own production facilities in Europe, Asia and America as well as sales subsidiaries and local commercial agencies in more than 110 countries.
Contact:
Sartorius AG
Petra Kirchhoff, +49 (0)551-308-1686
Vice
President of Group Communications and IR
petra.kirchhoff@sartorius.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Esri ArcGIS Location PlatformAdds Session Usage Pricing for Basemaps8.10.2025 20:44:00 CEST | Press release
New Model Offers Predictable, Flexible Cost Structure for High-Traffic and Long-Session Applications Esri, the global leader in location intelligence, today announced the release of a new session usage pricing model for basemaps available through ArcGIS Location Platform. This session usage model complements the existing tile usage pricing, which customers will still have the option to choose based on their operational needs. Developers and organizations will now have a more predictable and cost-effective way to integrate Esri’s high-quality basemaps into their applications and business systems. The additional pricing option for ArcGIS Location Platform is especially valuable for high-traffic applications or those with extended user sessions, such as real estate search portals, rideshare apps, or delivery tracking systems. By aligning pricing with actual user interactions—such as panning, zooming, and searching—developers can better forecast costs. “Organizations struggle with unpredic
Forum Invest in Senegal 2025 (Fii Senegal 2025): President Bassirou Diomaye Faye Calls for Investment in a Transforming Senegal8.10.2025 19:50:00 CEST | Press release
“Senegal offers a growing market within the framework of the Continental Free Trade Area, supported by a legal environment undergoing modernization and reform. We are ready to welcome you and facilitate your establishment and success. Come seize opportunities in high-potential strategic sectors and forge fruitful, mutually beneficial partnerships,” stated His Excellency President Bassirou Diomaye Faye at the opening of Forum Invest in Senegal 2025 (Fii Senegal 2025) (https://FiiSenegal.sn/). With these words, the Head of State set the tone for a forward-looking forum, symbolizing a Senegal firmly committed to the path of economic transformation, stability, and trust. The President reiterated the four pillars of Vision Senegal 2050—economic diversification, regional development, strengthened governance, and investment in human capital—as the guiding framework for the country’s long-term development. Following this, Bakary Séga Bathily, Director General of APIX, welcomed this direction,
Bacardi Legacy of Great Workplace Continues With Forbes Honor of “World’s Best Employers” in 20258.10.2025 17:25:00 CEST | Press release
Family-Owned Company Earns Top Rank Within Spirits Bacardi Limited is proud to once again land a spot on the Forbes’ list of the ‘World’s Best Employers 2025’ — proving that great people and a great culture never go out of style. The family-owned company is a repeat show on the global list which is based on more than 300,000 independent surveys conducted in more than 50 countries. Participants were asked whether they would recommend a company to family or friends, and to rate it based on such criteria as workplace environment, salary, and other key criteria. Bacardi, the world’s largest privately held international spirits company, earned the highest ranking of pure spirits companies coming in at #86. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008919280/en/ Bacardi legacy of great workplace continues. “Being recognized again by Forbes among the World’s Top Employers is a true testament to our culture and the dedicatio
DevvStream Reports BTC and SOL Reserves as Crypto-Treasury Program Accelerates8.10.2025 17:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today reported current holdings and progress under its crypto-treasury program, which is designed to add 24/7 liquidity and generate staking income. Portfolio snapshot (BitGo custody): Bitcoin ($BTC): approximately 22.229 BTC held, valued at (US) $2,716,162 as of October 7, 2025. Solana ($SOL): 12,110.98 SOL acquired year-to-date; 12,127.64 SOL staked, including rewards. Total SOL held is valued at (US) $2,718,489 as of October 7, 2025. USD balance: approximately (US) $1,280,000 in cash within BitGo. The Company has retained all digital-asset holdings accumulated under the program to date. The treasury is intended to create incremental income through SOL staking and establish on-chain readiness for tokenized real-world assets, including renewable-energy plants, energy-trading contracts, and other sustainability
Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product8.10.2025 16:51:00 CEST | Press release
A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device. FDA concludes “Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.’” Experts from Philip Morris International Inc. (NYSE: PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). The full-day meeting on October 7 was part of the FDA’s customary review of PMI’s request to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products (MRTPs), a necessary ste
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum